Anti-cancer property and DNA binding interaction of first row transition metal complexes: A decade update

Metal ions carry out a wide variety of functions, including acid-base/redox catalysis, structural functions, signaling, and electron transport. Understanding the interactions of transition metal complexes with biomacromolecules is essential for biology, medicinal chemistry, and the production of synthetic metalloenzymes. After the coincidental discovery of cisplatin, importance of the metal complexes in biochemistry became a top priority for inquiry. In this review, a decade update on various synthetic strategies to first row transition metal complex and their interaction with DNA through non-covalent binding are explored. Moreover, this effort provides an excellent analysis on the efficacy of theoretical and practical approaches to the systematic generation of new non-platinum based metallodrugs for anti-cancer therapeutics.

A multi-spectroscopic and molecular docking approach for DNA/protein binding study and cell viability assay of first-time reported pendent azide bearing Cu(II)-quercetin and dicyanamide bearing Zn(II)-quercetin complexes

In the current study, one new quercetin-based Zn(II) complex [Zn(Qr)(CNNCN)(H2O)2] (Complex 1) which is developed by condensation of quercetin with ZnCl2 in the presence of NaN(CN)2 and Cu(II) complex [Cu(Qr)N3(CH3OH)(H2O)] (complex 2) which is developed by the condensation reaction of quercetin and CuCl2 in presence of NaN3, are thoroughly examined in relation to their use in biomedicine. The results of several spectroscopic studied confirm the structure of both the complexes and the Density Functional Theory (DFT) study helps to optimize the structure of complex 1 and 2. After completion of the identification process, DNA and Human Serum Albumin (HSA) binding efficacy of both the investigated complexes are performed by implementing a long range of biophysical studies and a thorough analysis of the results unveils that complex 1 has better interaction efficacy with the macromolecules than complex 2. The binding efficacy of complex 1 is comparatively higher towards both macromolecules because of its pure groove binding mode during interaction with DNA and the presence of an extra H-bond during connection with HSA. The experimental host-guest binding results is fully validated by molecular docking study. Interestingly complex 1 shows better antioxidant properties than complex 2, as well as quercetin, and it has strong anticancer property with minimal damage to normal cells, which is proved by the MTT assay study. Better DNA and HSA binding efficacy of 1 may be the reason for the better anticancer property of complex 1.

Nickel Complexes Bearing ONS Chelating Ligands: A Promising Contender for In Vitro Cytotoxicity Effects on Human Pancreatic Cancer MIA-PaCa-2 Cells

The highly chronic human pancreatic cancer cell is one of the major reasons for cancerous death. Nickel complexes are recently gaining interest in anticancer activities on different types of cancer cells. Hence, in this study, we synthesized and characterized a series of ONS donor ligands [2-HO-C₆H₄-CH═N-(C₆H₄)-SH] (L1), [2-OH-3-OMe-C₆H₃-CH═N-(C₆H₄)-SH] (L2), [2-OH-3,5-(C(Me)₃)₂-C₆H₂-CH═N-(C₆H₄)-SH] (L3), [2-OH-C₆H₄-CH═N-(C₆H₄)-SMe] (L4), [2-OH-3-OMe-C₆H₃-CH═N-(C₆H₄)-SMe] (L5), [2-OH-3,5-(C(Me)₃)₂-C₆H₂-CH═N-(C₆H₄)-SMe] (L6) and their Ni(II) metal complexes [(MeOH)Ni(L1-L1-4H)] (1), [(MeOH)Ni(L2-L2-4H)] (2), [(MeOH)Ni(L3-L3-4H)] (3), [(L4-H)₂Ni] (4), [(L5-H)₂Ni] (5), and [(L6-H)₂Ni] (6). The single-crystal X-ray diffraction data of complexes 1 and 4 were collected to elucidate the geometry around the metal center. The anticancer activity of complexes 1-6 was investigated on human pancreatic cancer cell line MIA-PaCa-2, which revealed that complexes 4 and 6 were the most significantly effective in decreasing the cell viability of cancer cells at the lowest dose. The structure parameters obtained from single-crystal X-ray diffraction data are found to be in good agreement with the data from density functional theory and Hirshfeld surface analysis for complex 1.

Design, synthesis, and biological evaluation of dinuclear bismuth(III) complexes with Isoniazid-derived Schiff bases

Four dinuclear bismuth(III) Schiff-base complexes bearing Schiff-base ligands have been synthesized and structurally characterized by single-crystal X-ray diffraction, elemental analysis, and spectral techniques (FT-IR, NMR and MS). The analytical data reveal the bismuth(III) complexes possess 1:1 metal-ligand ratios. In vitro biological studies have revealed that bismuth(III) complexes displayed much higher antibacterial and antitumor activities than their parent ligands, which involves two gram-negative (S. aureus, B. subtili) and two gram-positive (E. coli, P. aeruginosa) bacteria, and human gastric cancer SNU-16 cells. The power-time curves of S. pombe exposed to tested compounds were detected by bio-microcalorimetry. Some thermokinetic parameters (k, P_max,t_G and Q_total) were derived based on the metabolic power-time curves, and their quantitative relationships with the concentrations (c) were further discussed.

Synthesis, characterisation, DNA binding, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and molecular docking studies of metal(II) complexes with 1,10-phenanthroline scaffold

A series of metal complexes containing Phenanthroline scaffold [ML] (L-1,10-Phenanthroline derivative comprises conjugated aromatic core and selenol group); M = Cu(II), Zn(II), Co(II) and Zn(II) ions were designed and synthesised to obtain effective anti-cholinesterase efficiencies of metal chelates. Analytical and spectroscopic studies were used to determine the structural features. An octahedral structure with moderate distortion was attributed to the above metal chelates based on spectroscopic data. The distorted octahedral geometry of copper(II) complex to DNA (K_b = 4.05 × 10⁵ M^-1) is stronger than that of ethidium bromide (EB) to DNA (K_b = 3.2 × 10⁵ M^-1), other metal complexes, respectively. The synthesised 1,10-Phenanthroline derivative had the best inhibitory effects against acetylcholinesterase (AChE) and butyrylcholinesterase, with IC₅₀ values of 0.45 and 3.6 M, respectively, which were lower than the reference molecules. As a result, nitrogen-containing heterocyclic compounds (H₂L) showed significant inhibitory profiles against the metabolic enzymes. Therefore, we believe that these experimental results may contribute to the development of new drug molecules particularly in the treatment of neurological disorders including glaucoma, Alzheimer's disease (AD) and diabetes. Docking, AChE and BuChE inhibition activities results revealed that ligand may be used for AD. The prepared 1,10-phenanthroline analogue, which has a high selectivity for AChE, may be studied further to find potential candidates for treating early-stage Alzheimer's symptoms.Communicated by Ramaswamy H. Sarma.

Syntheses, crystal structures of two Fe(III) Schiff base complexes with chelating o-vanillin aroylhydrazone and exploration of their bio-relevant activities

Two novel Fe(III) complexes, Fe(HL¹)₂Cl·1.25H₂O (1) and Fe(HL²)₂·Et₃NH·H₂O (2) (H₂L¹ = o-vanillin benzoylhydrazone, H₃L² = o-vanillin salicylhydrazone) are prepared. X-ray single crystal diffraction confirms that the hydrazone ligands can be chelated to iron centre resulting in a six-coordinate octahedral configuration. Both complexes show major intercalation effect to the herring sperm deoxyribonucleic acid (HS-DNA) with high binding constants of 2.01 × 10⁴ M^-1 and 2.24 × 10⁴ M^-1, respectively. Molecular docking studies reveal both complexes can intercalate at the gap of DC5-DG2 and DG6-DC1 base pairs of DNA hexamer (1Z3F). The interaction of the complex 1 with plasmid pBR322 DNA induces distinguishable alterations of the DNA morphology. Further, the structure of plasmid pBR322 DNA treated with complex 1 in the presence of ascorbic acid has been damaged probably due to the reactive oxygen species (ROS) generation. What's more, both complexes show high affinity with bovine serum albumin (BSA), the binding constants measured by fluorescence techniques are 5.75 × 10⁶ M^-1 and 4.39 × 10⁷ M^-1, respectively. Molecular docking demonstrates that the complexes prefer the binding pocket of site III (subdomain IIB) of BSA (PDB ID: 4F5S). Similarly, dynamic light scattering (DLS) reveals that the complexes not only bind to BSA but also induce bigger size aggregates as the concentration increases.

Crystal structures and biological properties of aroylhydrazone Ni(II) complexes

Three aroylhydrazone ligands ((Z)-N'-([2,2'-bithiophen]-5-ylmethylene)-2-hydroxybenzohydrazide, HL1; (Z)-N'-([2,2'-bithiophen]-5-ylmethylene)-3-hydroxybenzohydrazide, HL2; and (Z)-N'-([2,2'-bithiophen]-5-ylmethylene)-4-hydroxybenzohydrazide, HL3) and their complexes with nickel (Ni(L1)₂, 1; Ni(L2)₂, 2; Ni(L3)₂∙DMF, 3) were synthesized and characterized by ESI-MS, NMR, IR, UV-vis and elemental analysis techniques. The molecular structure of ligand (HL2) and complexes 1-3 was confirmed by single crystal X-ray crystallography. The single crystal X-ray structure of complexes 1-3 showed a distorted square planar geometry around the metal center, and the ligands adopt a bidentate chelating mode. The interaction of calf thymus (ctDNA) with nickel(II) complexes was explored using absorption, emission spectrum, viscosity, and circular dichroism methods. These complexes exhibited moderate affinity for ctDNA through groove binding modes. The most efficient DNA binder was complex 2. The interaction of the complexes with DNA has also been supported by molecular docking study and molecular dynamics simulation. An in vitro cytotoxicity study of the complexes found low activity against human cervical (Hela) and breast (MCF-7) cancer cell lines, with the best results for complex 2, where IC50 values are 86 μM and 92 μM respectively.

Binuclear Ni(II) complexes containing ONS donor Schiff base ligands: Preparation, spectral characterization, X-ray crystallography and biological exploration

Four binuclear Ni(II) complexes [[Ni₂(H-DEAsal-tsc)₂(μ-dppm)]·2Cl (1), [Ni₂(DEAsal-mtsc)₂(μ-dppm)] (2), [Ni₂(DEAsal-etsc)₂(μ-dppm)] (3) and [Ni₂(DEAsal-ptsc)₂(μ-dppm)] (4)] were synthesized from the ligands namely 4(N,N)-diethylaminosalicylaldehyde-4(N)-thiosemicarbazone [H₂-DEAsal-tsc] H₂L¹/4(N,N)-diethylaminosalicylaldehyde-4(N)-methyl thiosemicarbazone [H₂-DEAsal-mtsc] H₂L²/4(N,N)-diethylaminosalicylaldehyde-4(N)-ethyl thiosemicarbazone [H₂-DEAsal-etsc] H₂L³/4(N,N)diethylaminosalicylaldehyde-4(N)-phenyl thiosemicarbazone [H₂-DEAsal-ptsc] H₂L⁴ and 1,1'-bis(diphenylphosphino)methane (dppm) and characterized by a number of spectro analytical techniques. The molecular structure of complexes [Ni₂(H-DEAsal-tsc)₂(μ-dppm)]·2Cl (1) and [Ni₂(DEAsal-ptsc)₂(μ-dppm)] (4) have been confirmed by single crystal X-ray diffraction studies. The analysis indicated that in complex 1, the ligand [H₂-DEAsal-tsc] coordinated as monobasic tridentate donor through phenolic oxygen, azomethine nitrogen and thione sulfur atoms. However, in complex 4, the ligand [H₂-DEAsal-ptsc] behaved as dibasic tridentate donor with thiolate sulfur coordination. Their ability to bind with Calf Thymus Deoxyribonucleic acid (CT-DNA) and Bovine Serum Albumin (BSA) were analysed spectrometrically. Intercalative interaction of the complexes with DNA was confirmed by ethidium bromide (EB) displacement studies and DNA viscosity measurements. The interaction mechanism of the complexes with BSA was found as static. In vitro antiproliferative studies of the ligands and complexes in A549 (human lung carcinoma cancer), MCF-7 (human breast cancer) and HeLa (human cervical cancer) cell lines witnessed significant cytotoxic nature of the complexes with low IC₅₀ values (in μM) than the standard metallo-drug cisplatin. Further, the results of Lactate Dehydrogenase (LDH) and Nitric oxide (NO) release assays supported the effectiveness of the complexes on the above said cancer cells.

Synthesis, crystal structure, Hirshfeld surface analysis, DNA binding, DNA cleavage activity and molecular docking of a new Schiff base nickel(II) complex

A mononuclear nickel(II) complex, [Ni(o-van-tris)₂]·2H₂O (o-van-tris = Schiff base derived from o-vanillin and tris(hydroxymethyl)aminomethane), has been synthesized and structurally characterized. The single crystal structure shows a distorted octahedron geometry coordinated with Ni(II) atom, and 2 D plane structure has formed by O-H···O hydrogen bond interactions. An analysis to ascertain intermolecular interactions of the complex was performed based on the Hirshfeld surfaces and their associated two-dimensional fingerprint plots. The binding properties of the nickel(II) complex with CT-DNA have been investigated by spectroscopic methods and molecular docking. Absorption and fluorescence spectral studies reveal that the complex interacts with DNA through hydrogen bond and hydrophobic interactions with the DNA base pairs. Molecular docking studies show that the complex effectively docks in the major groove of DNA. The DNA cleavage experiment was performed by gel electrophoretic assay, indicating that DNA cleavage activity of the complex is concentration dependent and much sensitive to ionic strength. The efficient cleavage mediated via hydrolytically cleaving pathway.Communicated by Ramaswamy H. Sarma.

Protein binding and antioxidant studies of diimine based emissive surfactant-ruthenium(II) complexes

Biophysical interaction of amphiphilic fluorescent surfactant-ruthenium(II) complexes and its precursor ruthenium(II) complexes with drug carrying proteins such as bovine and human serum albumins (BSA and HSA) have been studied through the UV-visible absorption, fluorescence and circular dichroism spectroscopic techniques to correlate the impact of head and tail groups of the metallosurfactants towards the designing of metallodrugs for the biomedical applications. The obtained results showed that both precursor- and surfactant-ruthenium(II) complexes interact with BSA/HSA via ground state protein-complex formation and their quenching follows the static mechanism. The extent of protein quenching and binding parameters resulted that the surfactant-ruthenium(II) complexes effectively interact with protein compared to their precursor-ruthenium(II) complexes, and also those interaction have greatly influenced by the change in the head group size compared to change in the tail group length. Interestingly on increasing the temperature, the protein-complex binding strength was decreased for the precursor-ruthenium(II) complexes, those increased for the surfactant-ruthenium(II) complexes, probably due to the respective involvement of electrostatic and hydrophobic interactions as supported by the thermodynamics of protein-complex interaction. Moreover, the results from UV-visible, synchronous and circular dichroism studies confirmed the occurrence of conformational and micro environmental changes in BSA/HSA upon binding with these complexes. It is also noted that HSA has more binding affinity with surfactant-ruthenium(II) complexes compared to BSA. The free radical scavenging ability against DPPH, ABTS, NO and superoxide free radical assays suggested that surfactant-ruthenium(II) complexes have better free radical scavenging ability compared to precursor-ruthenium(II) complexes.Communicated by Ramaswamy H. Sarma.

Antitumor effects of novel nickel–hydrazone complexes in lung cancer cells

Two novel nickel(ii) complexes [NiL^I]·CH₃CN (1·CH₃CN) and [Ni(H₂L^II)(NCS)₂]·0.5H₂O (2·0.5H₂O) were fabricated and in in vitro experiments they both showed the dose dependent cytotoxicity and killed A549 lung cancer cells via an apoptotic pathway.

Copper(ii) complexes with NNO ligands: synthesis, crystal structures, DNA cleavage, and anticancer activities

Three novel copper(ii) complexes, Cu(L1)₂ (1), Cu(L2)₂·2DMF (2), and Cu(L3)₂·2DMF (3), were synthesized using three aroylhydrazone ligands, (E)-2-hydroxy-N'-(1-(pyrazin-2-yl)ethylidene)benzohydrazide (HL1), (E)-3-hydroxy-N'-(1-(pyrazin-2-yl)ethylidene)benzohydrazide (HL2) and (E)-4-hydroxy-N'-(1-(pyrazin-2-yl)ethylidene)benzohydrazide (HL3). The complexes were characterized by elemental analysis, infrared (IR), and Ultraviolet-visible light (UV-vis) spectroscopy. The X-ray crystal structures of the complexes all possess a distorted octahedral coordination geometry. Both an absorption spectral titration and a competitive binding assay (ethidium bromide, 4',6-diamidino-2-phenylindole (DAPI), and methyl green) revealed that complexes 2 and 3 bind readily to calf thymus DNA (ctDNA) through intercalative and minor groove binding modes. Complexes 2 and 3 also exhibited oxidative cleavage of supercoiled plasmid DNA (pUC19) in the presence of ascorbic acid as an activator. Cytotoxicity studies showed that complexes 2 and 3 possessed high cytotoxicities toward the HeLa human cervical cancer cell line, but weak toxicities toward the L929 normal mouse fibroblast cell line. We therefore have reason to believe that complexes 2 and 3 both show potential as promising anticancer candidate drugs.